Apicidin upregulates PHD2 prolyl hydroxylase gene expression in cervical cancer cells

Anti-Cancer Drugs

Volumn 21, Issue 6, 2010, Pages 619-624

  Durczak, Marta ^a   Jagodzinski, Paweł Piotr ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Apicidin; Cervical cancer; Prolyl hydroxylase

Indexed keywords

APICIDIN; BISULFITE; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROTEIN; PROTEIN PHD2; UNCLASSIFIED DRUG;

ARTICLE; C33A CELL; CANCER CELL; CASKI CELL; CELL VIABILITY; COMPETITIVE INHIBITION; CONTROLLED STUDY; CPG ISLAND; DEMETHYLATION; DRUG CYTOTOXICITY; DRUG EFFECT; ENZYME ANALYSIS; EXON; FEMALE; GENE EXPRESSION; GENE SEQUENCE; HELA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIHA CELL; TUMOR CELLS AND CELL LINES; TUMOR GROWTH; UPREGULATION; UTERINE CERVIX CANCER; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION; HUMANS; PEPTIDES, CYCLIC; PROCOLLAGEN-PROLINE DIOXYGENASE; UP-REGULATION; UTERINE CERVICAL NEOPLASMS;

EID: 77953495380     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328339848b     Document Type: Article

References (36)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94:153-156.
2. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348:518-527. (Pubitemid 36159887)
3. Osinsky S, Zavelevich M, Vaupel P. Tumor hypoxia and malignant progression. Exp Oncol 2009; 31:80-86.
4. Maxwell PH, Dachs GU, Gleadle JM, Nicholls LG, Harris AL, Stratford IJ, et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci U S A 1997; 94:8104-8109.
5. Liao D, Corle C, Seagroves TN, Johnson RS. Hypoxia-inducible factor- 1alpha is a key regulator of metastasis in a transgenic model of cancer initiation and progression. Cancer Res 2007; 67:563-572.
6. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A 1995; 92:5510-5514.
7. Tian H, McKnight SL, Russell DW. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev 1997; 11:72-82.
8. Jain S, Maltepe E, Lu MM, Simon C, Bradfield CA. Expression of ARNT, ARNT2, HIF1 and Ah receptor mRNAs in the developing mouse. Mech Dev 1998; 73:117-123.
9. Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, et al. HIF targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 2001; 292:464-468.
10. Yu F,White SB, Zhao Q, Lee FS. HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proc Natl Acad Sci U S A 2001; 98:9630-9635.
11. HirsiläM, Koivunen P, Gü nzler V, Kivirikko KI, Myllyharju J. Characterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor. J Biol Chem 2003; 278:30772-30780.
12. Berra E, Benizri E, Ginouvè s A, Volmat V, Roux D, Pouyssé gur J. HIF prolylhydroxylase 2 is the key oxygen sensor setting low steady-state in normoxia. EMBO J 2003; 22:4082-4090.
13. Luczak MW, Jagodziń ski PP. The role of DNA methylation in cancer development. Folia Histochem Cytobiol 2006; 44:143-154.
14. Turek-Plewa J, Jagodziń ski PP. The role of mammalian DNA methyltransferases in the regulation of gene expression. Cell Mol Biol Lett 2005; 10:631-647.
15. Thiagalingam S, Cheng KH, Lee HJ, Mineva N, Thiagalingam A, Ponte JF. Histone deacetylases: unique players in shaping the epigenetic histone code. Ann N Y Acad Sci 2003; 983:84-100.
16. Acharya MR, Sparreboom A, Venitz J, Figg WD. Rational development of histone deacetylase inhibitors as anticancer agents: a review. Mol Pharmacol 2005; 68:917-932.
17. Khan N, Jeffers M, Kumar S, Hackett C, Boldog F, Khramtsov N, et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J 2008; 409:581-589.
18. Noh JH, Song JH, Eun JW, Kim JK, Jung KH, Bae HJ, et al. Systemic cellcycle suppression by apicidin, a histone deacetylase inhibitor, in MDA-MB-435 cells. Int J Mol Med 2009; 24:205-226.
19. Kim JS, Lee S, Lee T, Lee YW, Trepel JB. Transcriptional activation of p21(WAF1/CIP1) by apicidin, a novel histone deacetylase inhibitor. Biochem Biophys Res Commun 2001; 281:866-871.
20. Han JW, Ahn SH, Park SH,Wang SY, Bae GU, Seo DW. Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and gelsolin. Cancer Res 2000; 60:6068-6074.
21. Ahn MY, Lee J, Na YJ, Choi WS, Lee BM, Kang KW, et al. Mechanism of apicidin-induced cell cycle arrest and apoptosis in Ishikawa human endometrial cancer cells. Chem Biol Interact 2009; 179:169-177.
22. Kim S, Kang JK, Kim YK, Seo DW, Ahn SH, Lee JC, et al. Histone deacetylase inhibitor apicidin induces cyclin E expression through Sp1 sites. Biochem Biophys Res Commun 2006; 342:1168-1173.
23. Wu LP, Wang X, Li L, Zhao Y, Lu S, Yu Y, et al. Histone deacetylase inhibitor depsipeptide activates silenced genes through decreasing both CpG and H3K9 methylation on the promoter. Mol Cell Biol 2008; 28:3219-3235.
24. Soilleux EJ, Turley H, Tian YM, Pugh CW, Gatter KC, Harris AL. Use of novel monoclonal antibodies to determine the expression and distribution of the hypoxia regulatory factors PHD-1, PHD-2, PHD-3 and FIH in normal and neoplastic human tissues. Histopathology 2005; 47:602-610.
25. Kato H, Inoue T, Asanoma K, Nishimura C, Matsuda T,Wake N. Induction of human endometrial cancer cell senescence through modulation of HIF- 1alpha activity by EGLN1. Int J Cancer 2006; 118:1144-1153.
26. Lee KA, Lynd JD, O'Reilly S, Kiupel M, McCormick JJ, LaPres JJ. The biphasic role of the hypoxia-inducible factor prolyl-4-hydroxylase, PHD2, in modulating tumor-forming potential. Mol Cancer Res 2008; 6:829-842.
27. Chan DA, Kawahara TL, Sutphin PD, Chang HY, Chi JT, Giaccia AJ. Tumor vasculature is regulated by PHD2-mediated angiogenesis and bone marrow-derived cell recruitment. Cancer Cell 2009; 15:527-538.
28. Aprelikova O, Pandolfi S, Tackett S, Ferreira M, Salnikow K, Ward Y, et al. Melanoma antigen-11 inhibits the hypoxia-inducible factor prolyl hydroxylase 2 and activates hypoxic response. Cancer Res 2009; 69:616-624.
29. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162:156-159.
30. Darkin-Rattray SJ, Gurnett AM, Myers RW, Dulski PM, Crumley TM, Allocco JJ, et al. Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase. Proc Natl Acad Sci U S A 1996; 93:13143-13147.
31. Eun DW, Ahn SH, You JS, Park JW, Lee EK, Lee HN, et al. PKCepsilon is essential for gelsolin expression by histone deacetylase inhibitor apicidin in human cervix cancer cells. Biochem Biophys Res Commun 2007; 354:769-775.
32. Cheong JW, Chong SY, Kim JY, Eom JI, Jeung HK, Maeng HY, et al. Induction of apoptosis by apicidin, a histone deacetylase inhibitor, via the activation of mitochondria-dependent caspase cascades in human Bcr-Ablpositive leukemia cells. Clin Cancer Res 2003; 9:5018-5027.
33. You JS, Kang JK, Lee EK, Lee JC, Lee SH, Jeon YJ, et al. Histone deacetylase inhibitor apicidin downregulates DNA methyltransferase 1 expression and induces repressive histone modifications via recruitment of corepressor complex to promoter region in human cervix cancer cells. Oncogene 2008; 27:1376-1386.
34. Kim SH, Ahn S, Han JW, Lee HW, Lee HY, Lee YW, et al. Apicidin is a histone deacetylase inhibitor with anti-invasive and anti-angiogenic potentials. Biochem Biophys Res Commun 2004; 315:964-970.
35. Kim SH, Jeong JW, Park JA, Lee JW, Seo JH, Jung BK, et al. Regulation of the HIF-1alpha stability by histone deacetylases. Oncol Rep 2007; 17:647-651.
36. Ellis L, Hammers H, Pili R. Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer Lett 2009; 280:145-153.